1 This study included 100 newborns with hypotension in the first 24 h of life, treated with either albumin or normal saline bolus and dopamine infusion when necessary. In the albumin group, the percentage of infants who achieved normal pressure 1 h after the first bolus, the degree of improvement and the duration of normal pressure were greater with lesser need for dopamine infusion. Surprisingly, the incidence of all intraventricular hemorrhage (IVH) in the normal saline group was significantly greater.
We wish to make some comments thereon. The two groups of very low birth weight patients are too small to determine whether the augmented IVH in the normal saline group has any statistical significance; the minimum sample size needed to compare the two groups is about 3000 patients. Using one-way analysis of variance, we did not find any statistical significance for all IVH (P ¼ 0.194) and for grade 3 and 4 IVH (P ¼ 0.145).
Intraventricular hemorrhage in very low birth weight is the result of various different factors such as fluctuating cerebral blood flow, systemic hypotension and consequent reperfusion, increased cerebral venous pressure, hypertension, hypercarbia, coagulation defects, vaginal delivery, vascular factors and extravascular factors.
Groves et al. 2 have recently demonstrated that infants with reduced systemic perfusion tend to have normal or high blood pressure in the first hours of life, suggesting that a high systemic vascular resistance may lead to reduced blood flow. In this study, low blood pressure did not correlate with poor perfusion. Miletin et al.
3 found a strong association between low superior vena cava flow and IVH in the first 24 h of life; Osborn et al. 4, 5 found substantial rates of death, morbidity and developmental impairments at 3 years of life in newborns with low superior vena cava flow. Which strategy is the most effective for improving the cardiovascular status of immature infants in the first day of life is unclear; 6 however, dobutamine seems to be more likely to determine a reduction in cardiac afterload and improve blood flow with moderate arterial dilatation. 7 We are convinced that hypotension of the newborn should be treated after determination of superior vena cava flow and right ventricular output; a determination to be performed by a neonatologist skilled in neonatal echocardiography.
In patients with a birth weight greater than 1500 g, IVH is rare. As demonstrated by the authors, the only beneficial effect in the use of albumine bolus in this group of patients was the reduction in the use of vasopressor; other outcomes were not improved. Thus, albumin use exposes this category of patients to infectious risks without producing any clear benefits.
Further multicenter randomized trials should be performed to determine the benefit of albumine infusion in hypotensive newborns. 
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Response to Dr Ghirardello
Journal of Perinatology (2008) 28, 586; doi:10.1038 /jp.2008 We appreciate the writer's interest and comments regarding our study. As our paper explains, our study was designed to reflect the common clinical practice of treating hypotension with judicious fluid therapy, and then pressor therapy for the non-responders. 1 Many questions still exist about the criteria for the diagnosis and treatment of hypotension (that is, different blood pressure charts and different choice of pressor agents).
The writer's comment that the study was not powered to look at intraventricular hemorrhage (IVH) is certainly true. We agree that to observe a difference in IVH between two therapies would involve many thousands of babies. Our study was not designed to look at IVH as a primary outcome measure. These were secondary measures, recorded in terms of standard therapy for low-birth-weight infants. As stated in our paper, the results were compared with IVH and high-grade IVH rates from our own neonatal intensive care unit during the period of study. We agree that IVH is multifactorial, and has been shown to be associated with, but not necessarily the result of, many risk factors.
We would support further studies, especially those using the superior vena cava flow parameters, 2 perhaps looking both at correlation with blood pressure, and responses to fluid therapy and pressors.
